Exact Sciences

Exact Sciences' Suite of Cancer Tests

Exact Sciences offers a comprehensive suite of tests designed to detect cancers at various stages, guide treatment decisions, and identify hereditary cancer risks. Their flagship product, Cologuard®, is a non-invasive, stool DNA-based colorectal cancer screening test that has revolutionized early detection methods. OncoExTra™ is another significant innovation, aimed at identifying advanced, metastatic, refractory, relapsed, or recurrent solid tumors. Additionally, Exact Sciences developed Oncoguard® Liver for early-stage hepatocellular carcinoma detection and Oncotype DX® for genomic testing in breast and colon cancer. Their hereditary cancer test, Riskguard™, and the multi-cancer early detection test, Cancerguard™, further exemplify their dedication to comprehensive cancer diagnostics.

Exact Sciences' Collaborations

Exact Sciences has formed strategic collaborations with leading medical research institutions to advance cancer screening technologies. Their partnership with the Mayo Clinic focuses on cancer screening and biomarker identification, significantly enhancing their research capabilities. Collaboration with Johns Hopkins University aims to develop cutting-edge multi-cancer screening technologies. Additionally, Exact Sciences works with TGen, an affiliate of City of Hope, on minimal residual disease testing, which is crucial for understanding cancer recurrence. These collaborations underscore Exact Sciences' commitment to innovation and excellence in cancer diagnostics.

Exact Sciences' Patient Support Programs

Exact Sciences prioritizes patient support through several dedicated programs. Their Patient Engagement Program is designed to ensure adherence to surveillance testing, providing essential follow-up for patients at risk. Additionally, the Patient Assistance Program offers financial aid to help patients access these critical tests at no cost, thereby alleviating economic barriers to cancer screening. These initiatives reflect Exact Sciences' commitment to patient care and their objective of making advanced cancer diagnostics accessible to all.

Exact Sciences' Focus on Health Equity

Exact Sciences is committed to promoting health equity by increasing access to cancer screening for underserved populations. They engage in community health initiatives and collaborate with organizations such as the National Minority Quality Forum and the American Indian Cancer Foundation. These efforts aim to address disparities in healthcare access and ensure that all individuals, regardless of socio-economic status, have the opportunity to benefit from early cancer detection and advanced diagnostic technologies.

Exact Sciences' Research and Development Initiatives

Exact Sciences is heavily invested in research and development to continually enhance their cancer detection technologies. They conduct numerous clinical studies to validate the performance of their tests and offer grants for research in areas such as colorectal cancer and multi-cancer early detection. Notable developments include the next-generation Cologuard test with improved performance metrics and a blood-based screening method for colorectal cancer. Their ongoing research efforts are critical in maintaining their position as leaders in the field of cancer diagnostics.